CytRx Corporation (CYTR)
Chart Events
Performance Outlook
| Previous Close | 0.1300 |
| Open | 0.1300 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1000 |
| Day's Range | 0.1300 - 0.1550 |
| 52 Week Range | 0.0900 - 4.7000 |
| Volume | |
| Avg. Volume | 190,145 |
| Market Cap | 6.249M |
| Beta (5Y Monthly) | 2.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3550 |
| Earnings Date | Aug 10, 2022 - Aug 15, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CYTR
Related Research
- CYTRX CORPDaily – Vickers Top Buyers & Sellers for 05/19/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.RatingFair ValueEconomic Moat3 days agoArgus Research
- Business Wire
CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock
LOS ANGELES, May 19, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series D Preferred Stock, par value $0.01 per share, for each outstanding share of the Company’s common stock held of record as of 5:00 pm Eastern Time on May 20, 2022. The outstanding shares of
- Business Wire
CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.
LOS ANGELES, May 17, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, is pleased to highlight the strategic purchase of arimoclomol by KemPharm, Inc. ("KemPharm").
- Business Wire
CytRx Partners with Oncology Development Expert to Advance LADR Platform
LOS ANGELES, April 20, 2022--CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.
